Chemoinformaics analysis of ent-15-Oxo-kaur-16-en-19-oic acid
| Molecular Weight | 316.441 | nRot | 1 |
| Heavy Atom Molecular Weight | 288.217 | nRig | 22 |
| Exact Molecular Weight | 316.204 | nRing | 4 |
| Solubility: LogS | -3.842 | nHRing | 0 |
| Solubility: LogP | 2.911 | No. of Aliphatic Rings | 4 |
| Acid Count | 1 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 4 |
| Atoms Count | 51 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 23 | No. of Aromatic Carbocycles | 0 |
| nHetero | 3 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 2 | No. Saturated Carbocycles | 4 |
| No. of Hydrogen atom | 28 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 20 | No. of Saturated Rings | 4 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 3 | No. of Arom Bond | 0 |
| nHA | 2 | APOL | 54.4762 |
| nHD | 1 | BPOL | 29.8258 |
| QED | 0.737 |
| Synth | 5.466 |
| Natural Product Likeliness | 3.215 |
| NR-PPAR-gamma | 0.96 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Accepted |
| Pgp-inh | 0.006 |
| Pgp-sub | 0 |
| HIA | 0.007 |
| CACO-2 | -5.162 |
| MDCK | 0.0000227 |
| BBB | 0.049 |
| PPB | 0.93874 |
| VDSS | 0.363 |
| FU | 0.044464 |
| CYP1A2-inh | 0.019 |
| CYP1A2-sub | 0.647 |
| CYP2c19-inh | 0.023 |
| CYP2c19-sub | 0.875 |
| CYP2c9-inh | 0.135 |
| CYP2c9-sub | 0.164 |
| CYP2d6-inh | 0.006 |
| CYP2d6-sub | 0.228 |
| CYP3a4-inh | 0.074 |
| CYP3a4-sub | 0.135 |
| CL | 0.839 |
| T12 | 0.145 |
| hERG | 0.005 |
| Ames | 0.101 |
| ROA | 0.407 |
| SkinSen | 0.082 |
| Carcinogencity | 0.295 |
| EI | 0.142 |
| Respiratory | 0.965 |
| NR-Aromatase | 0.785 |
| Antiviral | No |
| Prediction | 0.636702 |